IBM stock rebounds from a five-day slump after Accenture’s solid earnings signal resilience in tech consulting amid AI disruption fears.
LATEST ARTICLES
Foghorn Therapeutics and Eli Lilly don’t plan any future collaborations following the dissolution of a cancer-drug partnership.
Eli Lilly doubles down on its pipeline with new data for weight-loss pill Foundayo and next-generation combo drug EloraTZP.
Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn’t enough to justify the valuation.
Needham starts coverage of Pasqal at Buy, with analyst David Williams pointing to the quantum developer’s commercial traction and strong balance sheet.
The deal would give AstraZeneca exposure to a promising cancer treatment without acquiring the company outright.
UniQure says it still sees a path to regulatory approval for the drug candidate, AMT-130, even as the experimental gene therapy for Huntington’s disease falls hort in a recent study.
Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.
BofA Securities initiates coverage on IonQ at Buy, saying the company’s recent acquisitions are shaping it into a diversified play on quantum technology.
Microsoft and Amazon are expanding their footprint in quantum computing, even as a commercial breakout remains years away.
Notable insiders at the company, including its chief financial officer, unloaded millions of dollars worth of Dell stock.
Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company.
IonQ’s Superion 256 quantum computer will be the first system installed at Nvidia’s quantum research center.
Industry heavyweights like IonQ and Quantinuum are among the attendees of Quantum World Congress.
Immunovant halts development of its lead drug candidate, imeroprubart, in skin lupus following a trial miss.
Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.
Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market duopoly.
Novo Nordisk plans to launch at least five multi-blockbuster drugs by 2030 and is targeting pipeline drug sales of $23 billion by 2035.
Moderna’s personalized cancer vaccine, intismeran autogene, will feature at the annual meeting of the European Society for Medical Oncology.
HP Inc. says it expects personal computer unit volumes to fall by a mid-single-digit percentage point in 2027 as costs continue to rise.
of 95 pages